-
21.发明公开公开(公告)号：US20240139247A1
公开(公告)日：2024-05-02
申请号：US18408385
申请日：2024-01-09
Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Zelig ESHHAR , Tova WAKS , Anat GLOBERSON LEVIN , Moran RAWET SLOBODKIN
IPC: A61K35/17 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N5/10 , C12N15/63
CPC classification number: A61K35/17 , A61K39/001126 , A61K39/001129 , A61K39/3955 , A61K39/39558 , A61K39/4631 , A61P35/00 , C07K16/28 , C07K16/2896 , C07K16/3061 , C12N5/0636 , C12N5/10 , C12N15/63 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/569 , C07K2317/76 , C07K2319/03
Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
-
公开(公告)号：US20240117386A1
公开(公告)日：2024-04-11
申请号：US17768228
申请日：2020-10-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ron MILO , Shmuel GLEIZER , Niv ANTONOVSKY , Elad NOOR , Arren BAR-EVEN , Yehudit ZOHAR , Roee BEN NISSAN , Elad HERZ , Yinon Moise BAR-ON
CPC classification number: C12P1/04 , C07K14/195 , C12N1/20 , C12N9/0008 , C12N9/1205 , C12N9/88 , C12Y102/02001 , C12Y207/01019 , C12Y401/01039 , C12Y402/01001
Abstract: A recombinant bacteria which is genetically modified to express formate dehydrogenase (FDH), phosphoribulokinase (prk) and Ribulose-Bisphosphate Carboxylase/oxygenase (RuBisCo) is disclosed. The bacteria may be modified to be autotrophic.
-
公开(公告)号：US20240069042A1
公开(公告)日：2024-02-29
申请号：US18387593
申请日：2023-11-07
Applicant: NeuroQuest Ltd. , Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
Inventor： Xin Huang , Yihan Li , James Doecke , Michal Eisenbach-Schwartz , Baijun Gu
CPC classification number: G01N33/6896 , G01N33/582 , G01N2800/2821
Abstract: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
-
24.发明公开公开(公告)号：US20240065988A1
公开(公告)日：2024-02-29
申请号：US18376875
申请日：2023-10-05
Applicant: Yeda Research and Development Co. Ltd. , Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventor： Alon CHEN , Juan Pablo LOPEZ
IPC: A61K31/135 , A61K31/216 , A61P25/24
CPC classification number: A61K31/135 , A61K31/216 , A61P25/24
Abstract: A method of treating a psychiatric disorder in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an N-methyl-D-aspartate (NMDA) receptor antagonist and a therapeutically effective amount of a KCNQ channel activator. Pharmaceutical compositions comprising an NMDA receptor antagonist and a KCNQ channel activator are also disclosed.
-
25.发明授权公开(公告)号：US11884727B2
公开(公告)日：2024-01-30
申请号：US17186960
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P25/28 , A61P37/02 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/3955 , A61K39/39541 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K38/208 , A61K2300/00 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
Patent Agency Ranking
公开(公告)号：US20240026357A1
公开(公告)日：2024-01-25
申请号：US18221914
申请日：2023-07-14
Inventor： Alon CHEN , Sharon MANASHIROV , Andres Pablo MONTEFELTRO
IPC: C12N15/113 , A61K47/55 , A61K47/54 , A61P25/24
CPC classification number: C12N15/113 , A61K47/55 , A61K47/548 , A61P25/24 , C12N2310/141
Abstract: A composition of matter comprising a synthetic miR-135 molecule comprising a nucleic acid sequence of a miR-135b as set forth in SEQ ID NO: 37, and a complementary strand as set forth in SEQ ID NO: 40 is disclosed. A conjugate comprising a composition of matter comprising a synthetic miR-135 molecule and a cell-targeting moiety is also disclosed.
-
公开(公告)号：US20240010973A1
公开(公告)日：2024-01-11
申请号：US18226877
申请日：2023-07-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaqub HANNA , Sergey VIUKOV , Emilie WILDSCHUTZ , Noa NOVERSHTERN , Carine JOUBRAN , Segev NAVEH TASSA , Alejandro CASTREJON AGUILERA , Bernardo OLDAK , Shadi TARAZI , Francesco RONCATO
IPC: C12N5/073
CPC classification number: C12N5/0604 , C12N2506/03 , C12N2501/155 , C12N2501/115 , C12N2501/119 , C12N2501/91 , C12N2500/02
Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.
-
公开(公告)号：US20240009315A1
公开(公告)日：2024-01-11
申请号：US18229224
申请日：2023-08-02
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Gideon SCHREIBER , Jiri ZAHRADNIK , Amnon BAR-SHIR , Yinon RUDICH , Andrea GALISOVA
CPC classification number: A61K47/64 , A61K47/6911
Abstract: Particles having an ACE2 targeting moiety attached to an outer surface thereof are disclosed herein. The ACE2 targeting moiety comprises a polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD), wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501. Uses of the particles for treatment and diagnosis of diseases are also disclosed.
-
公开(公告)号：US20240009287A1
公开(公告)日：2024-01-11
申请号：US18234935
申请日：2023-08-17
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ravid STRAUSSMAN , Oded SANDLER , Reut RIFF
CPC classification number: A61K39/0011 , A61P35/00 , A61K2039/52 , A61K2039/6006 , A61K2039/627
Abstract: A vaccine comprising a pharmaceutically acceptable carrier and bacteria which presents at least one cancer-associated antigen is disclosed. The bacteria are not genetically modified to express the at least one cancer-associated antigen. Uses thereof are also disclosed.
-
公开(公告)号：US20230419149A1
公开(公告)日：2023-12-28
申请号：US18299792
申请日：2023-04-13
Inventor： Gil SEMO , Ziv AQUA , Oded MELAMED , Dan CHARASH , Serge ROSENBLUM , Barak DAYAN
Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.059 seconds)
